Neither version of the vaccine has been authorized for use in the U.S. "We're encouraged by these data and the potential path forward for a combination COVID-19-influenza vaccine as well as stand-alone vaccines for influenza and COVID-19." Glenn, president of research and development for Novavax, said in a statement. "We continue to evaluate the dynamic public health landscape and believe there may be a need for recurrent boosters to fight both COVID-19 and seasonal influenza," Dr.
#NOVAVAX INFORMATION TRIAL#
A second phase of the trial is set to begin "by the end of 2022."Īhead of Indiana's near-total abortion ban, Illinois adds measures to protect reproductive rights The company said its first phase of the trial showed the potential for triggering an antibody response to both viruses, though further study is needed. Novavax's vaccine has not been linked to myocarditis.īut in addition, the company is also in clinical trials of a version of its vaccine that would target both COVID and flu at the same time. Scientists then extract and purify the protein and then mix in an immune-boosting chemical.įor certain groups of people - particularly young men - the mRNA vaccines carry a slightly elevated risk of a heart condition called myocarditis. The Maryland-based Novavax drugmaker uses genetic engineering to grow harmless copies of the coronavirus spike protein in insect cells.
The Novavax vaccine differs from Pfizer and Moderna's mRNA vaccines in that it relies on an older technology that’s been used for years to make shots for diseases like influenza and pertussis. Sign up for the weekly Chicago Catch-Up newsletter here. Feeling out of the loop? We'll catch you up on the Chicago news you need to know.
0 kommentar(er)
